iRadimed (NASDAQ:IRMD) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

iRadimed (NASDAQ:IRMD) issued its earnings results on Friday. The medical equipment provider reported $0.46 EPS for the quarter, topping the consensus estimate of $0.44 by $0.02, FiscalAI reports. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The company had revenue of $20.47 million for the quarter, compared to the consensus estimate of $20.35 million. iRadimed updated its FY 2026 guidance to 2.090-2.240 EPS and its Q3 2026 guidance to 0.540-0.590 EPS.

Here are the key takeaways from iRadimed’s conference call:

• Strong customer demand for the new 3870 pump drove bookings to more than double units shipped, with roughly 70% of replacement orders using four-channel quad systems and ASPs exceeding $110,000.
• IRadimed achieved its target of producing more than 130 3870 pumps in Q2 and plans to exceed 300 units in Q3, with startup costs expected to decline by more than 50% as manufacturing efficiencies improve.
• Q2 revenue was essentially flat year over year at $20.5 million, while gross margin fell to 74% from 78% and GAAP EPS declined to $0.41 from $0.45 due to the initial 3870 production ramp.
• Recurring revenue trends remained healthy, including 14% growth in disposables, while domestic patient-monitor sales reached a record 71 units and the company cited strong backlogs across pumps, monitors, and ferromagnetic detection systems.
• Management reaffirmed full-year 2026 guidance of $91 million–$96 million in revenue and $1.90–$2.05 in GAAP EPS, expects improving margins through the second half, and said a $100 million revenue run rate in Q4 is within reach.

iRadimed Trading Down 4.6%

Shares of iRadimed stock opened at $90.86 on Friday. iRadimed has a 12 month low of $57.83 and a 12 month high of $107.90. The firm has a market capitalization of $1.16 billion, a P/E ratio of 50.76 and a beta of 0.90. The business has a fifty day simple moving average of $94.54 and a two-hundred day simple moving average of $95.70.

iRadimed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 28th. Shareholders of record on Friday, August 14th will be issued a $0.20 dividend. The ex-dividend date is Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s dividend payout ratio is 43.72%.

iRadimed News Summary

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Earnings exceeded expectations. iRadimed reported second-quarter non-GAAP diluted EPS of $0.46, above the $0.42 consensus estimate; GAAP diluted EPS was $0.41. The company also reported a 24.48% return on equity and a 27.36% net margin. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: 2026 EPS guidance is above analyst expectations. Full-year EPS guidance of $2.09-$2.24 compares with the $1.96 consensus estimate. Third-quarter EPS guidance of $0.54-$0.59 also exceeds the $0.53 consensus. IRADIMED Corporation Q2 2026 Earnings Call Transcript
• Positive Sentiment: iRadimed declared a regular quarterly dividend of $0.20 per share, providing a direct shareholder return. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Revenue guidance is broadly in line with expectations. Third-quarter revenue guidance of $23.0-$24.5 million brackets the $23.7 million consensus, while full-year guidance of $91-$96 million is close to the $91.2 million estimate.
• Negative Sentiment: Revenue growth was weak. Second-quarter revenue reached $20.5 million, up only $0.1 million, or 0.5%, from the prior-year period. That modest growth may have tempered the positive impact of the EPS beat, particularly with shares trading at a trailing price-to-earnings ratio near 50.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $120.00.

Insider Buying and Selling at iRadimed

In related news, CEO Roger E. Susi sold 2,500 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $90.60, for a total value of $226,500.00. Following the completion of the transaction, the chief executive officer directly owned 2,162,500 shares in the company, valued at $195,922,500. This trade represents a 0.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 21,250 shares of company stock valued at $1,836,403. 34.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On iRadimed

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. increased its stake in shares of iRadimed by 410.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock valued at $24,893,000 after purchasing an additional 205,783 shares in the last quarter. Invesco Ltd. grew its stake in shares of iRadimed by 473.9% in the 4th quarter. Invesco Ltd. now owns 35,131 shares of the medical equipment provider’s stock worth $3,418,000 after buying an additional 29,010 shares during the last quarter. NewEdge Advisors LLC purchased a new stake in shares of iRadimed in the 4th quarter worth approximately $1,679,000. XTX Topco Ltd purchased a new stake in shares of iRadimed in the 4th quarter worth approximately $360,000. Finally, Susquehanna Portfolio Strategies LLC bought a new position in iRadimed during the 4th quarter valued at approximately $326,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.